Your session is about to expire
← Back to Search
CUDC-907 for Tumors
This trial is testing a new drug to see if it can help kids with solid tumors, lymphoma, or brain tumors that haven't responded to other treatments.
- Brain Tumor
- Solid Tumors
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2019 Phase 2 trial • 70 Patients • NCT02674750
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You cannot be taking high doses of corticosteroid medication, unless it's for cancer that has spread to the brain.You have had allergic reactions to drugs similar to CUDC-907 in the past.You have a serious illness or infection that is not under control, or you have a heart condition or mental health issue that could make it hard for you to follow the study rules.You have been diagnosed with HIV, hepatitis B, or hepatitis C.You have been diagnosed with type 1 or type 2 diabetes.You have a stomach or intestine problem that could prevent your body from absorbing CUDC-907.Participants must be between 1 and 21 years old when they join the study.You are able to perform daily activities at a certain level as determined by your doctor.Your disease must be able to be measured or evaluated.You have been diagnosed with solid tumors, brain tumors, or lymphoma based on a biopsy or surgery.You have a disease that has come back or is not responding to standard treatments.You must have a body size of at least 0.5 square meters.
- Group 1: CUDC-907
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is geriatric participation being considered for this research project?
"As per the prerequisites for enrolment, this clinical trial has a lower age limit of 1 year old and an upper age cap of 21."
Are there any vacancies remaining in this clinical trial?
"Affirmative. The details available on clinicaltrials.gov declare that this medical trial is currently recruiting participants, and the first posting was in October 1st 2016. 44 patients are needed from 4 different sites, with the information being most recently updated in August 13th 2022."
How many healthcare facilities are administering this experiment?
"Several medical centres are accepting patients for this research trial, such as Dana Farber Cancer Institute in Boston, Children's Hospital of Philadelphia in Philadelphia, and University of Californiar Cancer Institute in Boston, Children's Hospital of Philadelphia in Philadelphia, and University of California at San Francisco Benioff Children's Hospital."
Is this clinical investigation pioneering a new approach?
"Since its inception in 2016, CUDC-907 has been subject to a plethora of studies. Initially sponsored by Curis, Inc., the first trial involving 44 participants ultimately led to Phase 1 drug approval. Currently, two trials are ongoing over 19 cities and 2 countries."
Has the FDA sanctioned CUDC-907 for commercial use?
"The safety of CUDC-907 was ranked a 1 due to the lack of data and clinical trials, signifying that it is in its initial stages."
Could you outline the other investigations that have taken place with CUDC-907?
"Presently, there are two trials for CUDC-907 in progress; neither of which currently occupy Phase 3. Baltimore serves as the hub for many of these investigations, though 24 other locations scattered throughout the US also administer clinical tests with this medication."
How many individuals have registered to be part of this research?
"In order to effectively conduct this trial, 44 eligible participants must be recruited. Curis, Inc., the sponsor of the study will manage it from locations such as Dana Farber Cancer Institute in Massachusetts and Children's Hospital of Philadelphia in Pennsylvaniaber Cancer Institute in Massachusetts and Children's Hospital of Philadelphia in Pennsylvania."
Is my eligibility criteria sufficient to become involved in this research?
"This medical experiment is looking to enrol 44 individuals with lymphoma between 1 and 21 years of age. In order for a patient to be eligible, they must possess either histologically confirmed solid tumors, CNS tumours or lymphoma that can be identified through biopsy/surgery at initial diagnosis or relapse/progression; the only exception being pediatric patients diagnosed exclusively by imaging criteria (diffuse intrinsic pontine gliomas and optic pathway gliomas). Furthermore, participants must have measurable disease in both parts A and B that has relapsed/refractory responses towards standard treatments."
Share this study with friends